Early-Stage Fund
Redesigning the act of innovation for Neurodiversity

Over $268 B was spent on autism services in 2015, projected to be $450 B by 2024. Less than 1% of that spending has gone towards Neurodevelopmental Disorders (NDD) tech and life sciences research and development. Compare that to 23% going to cancer research versus services.

Focus on human services has crowded out investments in tech and life sciences, yet a single piece of technology can help more effectively in some cases than multiple aides. Neuvation Ventures plans to change this.

To achieve the goal of adding new companies and products, we need to focus more on translational research and early-stage companies in digital health, diagnostics, and therapeutics still in ideation. There needs to be fundamental changes on how to approach the new solutions and that requires us to rethink how technology and life sciences are utilized for NDD.